Merck partially regains its breakthrough tag for hep C combo

Merck ($MRK) execs weren't happy when the FDA stripped its breakthrough therapy designation for their closely watched hepatitis C combo. But the agency has now relented--at least partly. The pharma giant said it's getting two new BTD titles in small subgroups of patients to replace the broader breakthrough tag that it lost. Report

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

Roche’s Tecentriq didn't repeat its prior TNBC success when tested in tandem with chemo med paclitaxel in previously untreated metastatic patients.

Alexion Pharmaceuticals names its first chief diversity officer as the rare disease specialist looks to cultivate diversity and inclusion.